Galena implodes as trial monitors call a halt to a failed PhIII cancer study
Shares of Galena ($GALE) were eviscerated this morning, dropping 78% after the biotech announced that it had stopped a Phase III study of its lead cancer vaccine NeuVax after the monitoring committee flagged it for failing to help breast cancer victims.
Proving yet again that an entire wave of cancer vaccines has been a disappointing flop, the San Ramon, CA-based biotech says it will now assess the program — but it doesn’t look good.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.